SCHEMBL15575225

SCHEMBL15575225

CNC(=O)c1cc(Oc2ccc(CNC(=O)Nc3cc(Cl)ccc3OC)cc2F)ccn1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 3/20 0.83
P2RX3 P56373 4/20 0.52
RAF1 P04049 6/20 0.51
KDR P35968 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.47
CSF1R P07333 1/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
RIPK2 O43353 1/20 0.44
ABCB11 O95342 1/20 0.44
ABL1 P00519 1/20 0.44
NR3C1 P04150 1/20 0.44
RET P07949 1/20 0.44
HTR1A P08908 1/20 0.44
PDGFRB P09619 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16990616 0.92 DDR2 (0.70) DDR2P2RX3RAF1KDRL3MBTL1
SCHEMBL13603518 0.91 DDR2 (1.00) DDR2P2RX3RAF1L3MBTL1CSF1R
SCHEMBL15574169 0.90 DDR2 (0.82) DDR2P2RX3RAF1KDRL3MBTL1
SCHEMBL15574418 0.90 DDR2 (0.72) DDR2P2RX3RAF1KDRL3MBTL1
SCHEMBL15574564 0.90 DDR2 (0.72) DDR2P2RX3RAF1KDRL3MBTL1
SCHEMBL15574738 0.89 RAF1 (0.67) DDR2RAF1KDRL3MBTL1CSF1R
SCHEMBL15574177 0.87 DDR2 (0.65) DDR2P2RX3RAF1KDRCSF1R
SCHEMBL15574835 0.86 DDR2 (0.61) DDR2L3MBTL1KMT2AMEN1ALDH1A1
SCHEMBL171246 0.83 DDR2 (0.86) DDR2P2RX3RAF1KDRCSF1R
SCHEMBL13603632 0.83 DDR2 (0.72) DDR2P2RX3RAF1KDRCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP claimed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO claimed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885P2RX3 540/4885RAF1 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.